USAntibiotics's plant in Tennessee is one of the last plants in the United States that makes amoxicillin, the crucial antibiotic that has been in shortage in some forms since 2022. But the plant isn’t breaking even, financially. WSJ’s Liz Essley Whyte reports on why it is so hard for American-made generic drugs manufacturers to survive.
Further Listening:
- Will Florida’s Plan to Get Cheap Drugs From Canada Work?
- Trillion Dollar Shot
Further Reading:
- Drug Shortages in America Reach a Record High
- Drug Shortages Trigger FTC Probe
Learn more about your ad choices. Visit megaphone.fm/adchoices
The Big Short: China Edition
The Trustbuster Taking on Ticketmaster
$2.8 Billion for College Athletes and a New World for the NCAA
Introducing Science Vs - Ozempic: Is It Scarier Than We Thought?
The First Person to Get Elon Musk’s Neuralink Brain Chip
Could Paris Hilton Create the 'Next Disney?'
Years After Surfside Collapse, Florida Condos Are In Crisis
Why Israel and Hamas Could Be Headed Into a Forever War
Did ‘Roaring Kitty’ Just Spark a Meme Stock Sequel?
Trillion Dollar Shot, Episode 2: Bank Breakers
The Race to Save an Iconic Train From Falling Into the Ocean
The Life of One of Wall Street’s Greatest Investors
Live from Seattle: A Weird Economy + Election = ??
North Korea’s Propaganda Mastermind
How FTX Found Billions to Repay Customers
Trillion Dollar Shot, Episode 1: Birth of a Blockbuster
A Lawyer Says He Doesn't Need Help for Psychosis. His Family Disagrees.
Can Chinese Customers Rescue Starbucks?
The Suitcases Full of Cash Flowing Through Airports
Why Is Tesla Pulling Back on EV Charging?
Create your
podcast in
minutes
It is Free
WSJ Tech News Briefing
WSJ What’s News
WSJ Opinion: Potomac Watch
WSJ Your Money Briefing
The Indicator from Planet Money